Bridging Cultural Differences to Improve HBV Treatment
in Asian and Other Diverse Communities

Advanced Certificate Program III:

Home

Sign In

About

Curriculum

Library

Ask the Experts

Resources

Additional Information

Target Audience

Program Goal

Learning Objectives

CME/CE Information

CME/CE

Contract

Disclosures

Faculty

Roster

Disclosures

Technical Requirements

Update Profile

Contact Us

These independent CME /CE activities are supported by an educational grant from Bristol-Myers Squibb.

Keep up to date with us via twitter!

Projects In Knowledge
Overlook at Great Notch
150 Clove Road
Little Falls, NJ 07424
Tel: (973) 890-8988
Fax: (973) 890-8866

Projects In Knowledge is pleased to present Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities.

Hepatitis B virus (HBV) is an infectious disease of considerable national and international concern. This CME and CE program features state-of-the-science information on HBV disease burden, HBV replication and transmission, screening for HBV, hepatitis B treatment options, and hepatitis B management.

The curriculum offered promises to be a timely source of information that can be immediately used in caring for patients infected with chronic hepatitis B.

Co-Chairs:

	Adrian M. Di Bisceglie, MD, FACP Acting Chairman, Internal Medicine Chief of Hepatology Saint Louis University School of Medicine St. Louis, Missouri

	Robert G. Gish, MD Medical Director Liver Transplant Program Chief, Division of Hepatology and Complex GI California Pacific Medical Center San Francisco, California

Program Features:

Timely and relevant information
CME credit and CE credit provided
E-mail notification when a new course becomes available
Periodic program updates, news, and announcements
Certificate of Advanced Study in Hepatitis B Management awarded upon completion of all 19 course posttests and evaluations

Curriculum Overview

This intensive, yearlong curriculum explores hepatitis B virus (HBV) infection with regard to

Latest anti-HBV treatment guidelines and clinical implications
Assessing at-risk individuals for hepatitis B — special populations
Hepatitis B virus infection —Acute and chronic basics
- HBV disease burden — cirrhosis, hepatocellular carcinoma (HCC), morbidity/mortality
- HBV replication and transmission
- Screening for HBV infection
- Serologic and molecular testing should include
  - Viral antigens: HBsAg — acute or chronic infection, HBeAg — acute or chronic infection
  - Viral antibodies: anti-HBs — marker of immunity, anti-HBc — marker of infection, anti-HBe — low infectivity
  - Molecular tests: HBV DNA — acute or chronic infection
Hepatitis B virus treatment options and strategies
- Current and emerging therapies: efficacy, safety, and resistance profiles — interferon alfa 2-a or interferon alfa 2-b (IFN α-2a or IFN α-2b), pegylated interferon alfa 2-a or pegylated interferon alfa 2-b (PEG IFN α-2a or PEG IFN α-2b), lamivudine (LAM, LMV, LVD, 3TC), adefovir (ADV), entecavir (ETV, ENT), telbivudine (LdT, TBV), and investigational agents such as clevudine and emtricitabine
- Managing treatment-naive patients, treatment-experienced patients (Nonresponders and Relapsers), Consolidation therapy, Combination therapy, Special populations

Learning Objectives:

Understand the impact of cultural differences in the management of HBV infection, with focus on the Asian and Pacific Islander community.
Assess the role of HBV DNA and other markers in determining when to treat and treatment selection in HBV-infected patients with diverse ethnic backgrounds, and in evaluating on-treatment response to therapy to improve patient outcomes.
Formulate anti-HBV treatment strategies, considering safety, efficacy, endpoints, and resistance patterns of currently available and emerging antiviral agents as well as cultural differences among patients, to improve response rates in patients with HBV infection.
Integrate prescribing and monitoring strategies to help prevent or reduce the emergence of resistance into individualized anti-HBV treatment plans for infected patients.

These independent CME/CE activities are supported by an educational grant from

View Public Service Announcement
Video on HBV

In 2006, the Asian Pacific American Medical Student Association (APAMSA) enlisted two medical students to create a public service announcement urging the Asian Pacific American community to get screened and vaccinated for hepatitis B.

The result was a spoken word performance piece that has generated widespread acclaim for its innovation and effectiveness.
Click here to view this video.

Covered Topics Include

AASLD, Keeffe, and APASL Hepatitis B virus Treatment Guidelines
HBV Basics — including virology and genotype
Assessing At-Risk Individuals for HBV - Special Populations
Screening and Diagnosis in the Asian Community
Chronic HBV Disease Burden
HBV Treatment Options and Strategies
HBV Treatment Resistance - Detection and Management

Treatment Strategies Discussed

AASLD, Keeffe, and APASL HBV Treatment Guidelines
Treatments
- (Peg)interferon
- Oral Nucleosides/Nucleotides: Lamivudine, Adefovir, Entecavir, Telbivudine
- Investigational Drugs: Emtricitabine, Tenofovir, Clevudine
- Combination Therapy
Treatment Endpoints and Duration
Monitoring for Treatment Response

Hepatitis News powered by

About the Program